Skip to main content
Archie Tse, MD, Oncology, New York, NY

ArchieNTseMD

Oncology New York, NY

Physician

Dr. Tse is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

  • Connect with other colleagues in the same hospital or clinic
  • Search all U.S. specialist profiles and refer a patient
  • Read the latest clinical news and earn CME/CEU credits

See Dr. Tse's full profile

Already have an account?

Education & Training

  • Memorial Sloan Kettering Cancer Center
    Memorial Sloan Kettering Cancer CenterFellowship, Hematology and Medical Oncology, 2000 - 2003
  • UCLA David Geffen School of Medicine/UCLA Medical Center
    UCLA David Geffen School of Medicine/UCLA Medical CenterResidency, Internal Medicine, 1997 - 2000
  • Keck School of Medicine of the University of Southern California
    Keck School of Medicine of the University of Southern CaliforniaClass of 1997

Certifications & Licensure

  • NY State Medical License
    NY State Medical License 2002 - 2025

Clinical Trials

Publications & Presentations

PubMed

Press Mentions

  • CStone Presents Research Data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021
    CStone Presents Research Data of CS5001 (ROR1 ADC) at the 33rd AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics 2021October 8th, 2021
  • CStone Presents Preliminary Results from a Phase Ib Study of the Anti-CTLA-4 Monoclonal Antibody (mAb) CS1002 in Combination with the Anti-PD-1 mAb CS1003 in Patients with Advanced Solid Tumors at ESMO 2021
    CStone Presents Preliminary Results from a Phase Ib Study of the Anti-CTLA-4 Monoclonal Antibody (mAb) CS1002 in Combination with the Anti-PD-1 mAb CS1003 in Patients with Advanced Solid Tumors at ESMO 2021September 19th, 2021
  • CStone Received China NMPA IND Approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA Multi-Specific Antibody, Marking Further Expansion of Its Pipeline 2.0
    CStone Received China NMPA IND Approval for CS2006/NM21-1480, a PD-L1/4-1BB/HSA Multi-Specific Antibody, Marking Further Expansion of Its Pipeline 2.0September 15th, 2021
  • Join now to see all

Grant Support

  • Targeting Cell Cycle Checkpoints In Cancer TherapeuticsNational Cancer Institute2006–2009